The objectives of the project are:

to contribute to the diagnostic pathway for patients affected by known forms of limb girdle muscular dystrophy
to contribute to the improvement of the diagnostic awareness of rare neuromuscular diseases among physicians
to speed up the integration of next-generation sequencing technologies into healthcare

The focus on undiagnosed patients with a defined clinical phenotype enables increased diagnostic rates for disease causing mutations in known genes in this cohort. Whole exome sequencing also provides scope both for new gene discovery and for additional research into disease modifiers and genotype‐phenotype correlations.

Project start date – August 2014
Project end date – December 2020

Funded by Genzyme, Kurt + Peter foundation, LGMD2D, LGMD2iFund, Samantha J Brazzo Foundation and Ultragenyx

Coordinated by

Professor Volker Straub